Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 201–300 of 1,004
HDL abnormalities in nephrotic syndrome and chronic kidney disease
Vaziri, N. D. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.180 · Cited by 166
Targeting Vascular Calcification in Chronic Kidney Disease
Nelson, A. J., Raggi, P., Wolf, M., Gold, A. M., Chertow, G. M., & Roe, M. T. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.002 · Cited by 161
Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis
Upadhyay, A., Earley, A., Lamont, J. L., Haynes, S., Wanner, C., & Balk, E. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00005 · Cited by 166
Self-citationCardiovascular risk in the peritoneal dialysis patient
Krediet, R. T., & Balafa, O. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.68 · Cited by 164
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
Hayward, R. A., Hofer, T. P., & Vijan, S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 164
Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review
Green, D., Roberts, P. R., New, D. I., & Kalra, P. A. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.02.376 · Cited by 166
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Self-citationHDL metabolism and activity in chronic kidney disease
Vaziri, N. D., Navab, M., & Fogelman, A. M. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.36 · Cited by 163
Jafri, H., Alsheikh-Ali, A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 162
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Rahimi, K., Emberson, J., McGale, P., Majoni, W., Merhi, A., Asselbergs, F. W., Krane, V., Macfarlane, P. W., & Executive, P. I. A. O. B. O. T. P. (2011) · BMJ · doi:10.1136/bmj.d1250 · Cited by 159
Self-citationChertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J. D., Goodman, W. G., London, G. M., Mahaffey, K. W., Moe, S. M., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04381206 · Cited by 160
Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
Chen, S.-C., & Tseng, C.-H. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.88 · Cited by 152
Pasch, A., Block, G. A., Bachtler, M., Smith, E. R., Jahnen‐Dechent, W., Arampatzis, S., Chertow, G. M., Parfrey, P. S., Ma, X., & Floege, J. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04720416 · Cited by 160
Sudden Cardiac Death Among Hemodialysis Patients
Makar, M. S., & Pun, P. H. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.006 · Cited by 165
HMG CoA reductase inhibitors (statins) for dialysis patients
Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub3 · Cited by 158
Guideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 189
Kovesdy, C. P., Anderson, J. E., & Kalantar-Zadeh, K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060674 · Cited by 159
Early Outcomes among Those Initiating Chronic Dialysis in the United States
Chan, K. E., Maddux, F. W., TOLKOFF-RUBIN, N. E., Karumanchi, S. A., Thadhani, R., & Hakim, R. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03680411 · Cited by 154
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 171
Antioxidants for chronic kidney disease
Jun, M., Venkataraman, V., Razavian, M., Cooper, B. A., Zoungas, S., Ninomiya, T., Webster, A. C., & Perkovic, V. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008176.pub2 · Cited by 159
Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk
Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv352 · Cited by 150
Self-citationArterial disease in chronic kidney disease
Moody, W. E., Edwards, N. C., Chue, C. D., Ferro, C. J., & Townend, J. (2012) · Heart · doi:10.1136/heartjnl-2012-302818 · Cited by 153
Karp, I., Behlouli, H., LeLorier, J., & Pilote, L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.12.011 · Cited by 151
Palmer, S. C., Nistor, I., Craig, J. C., Pellegrini, F., Messa, P., Tonelli, M. A., Covic, A. C., & Strippoli, G. F. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001436 · Cited by 151
Obesity Paradox in Patients on Maintenance Dialysis
Kalantar‐Zadeh, K., & Kopple, J. D. (2006) · KARGER eBooks · doi:10.1159/000095319 · Cited by 161
Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147
Self-citationRunx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice
Lin, M.-E., Chen, T., Leaf, E. M., Speer, M. Y., & Giachelli, C. M. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.03.020 · Cited by 157
Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment
Tsimihodimos, V., Dounousi, E., & Siamopoulos, K. C. (2008) · American Journal of Nephrology · doi:10.1159/000144024 · Cited by 146
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg, H. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2084 · Cited by 145
Lipid lowering efficacy of atorvastatin
Adams, S. P., Tsang, M., & Wright, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub2 · Cited by 126
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojakovic, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 145
Self-citationMathew, R. O., Bangalore, S., Lavelle, M. P., Pellikka, P. A., Sidhu, M. S., Boden, W. E., & Asif, A. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.049 · Cited by 146
Disorders of Lipid Metabolism in Chronic Kidney Disease
Bulbul, M. C., Dağel, T., Afşar, B., Ulusu, N. N., Kuwabara, M., Covic, A. C., & Kanbay, M. (2018) · Blood Purification · doi:10.1159/000488816 · Cited by 163
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 155
Heinz, J., Kropf, S., Domröse, U., Westphal, S., Borucki, K., Luley, C., Neumann, K. H., & Dierkes, J. (2010) · Circulation · doi:10.1161/circulationaha.109.904672 · Cited by 142
Review of the Effects of Omega-3 Supplementation in Dialysis Patients
Friedman, A., & Moe, S. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00740805 · Cited by 142
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa‐Rotter, R., Dehmel, B., Drüeke, T. B., Floege, J., Kubo, Y., Mahaffey, K. W., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001363 · Cited by 142
Roberts, M. A., Polkinghorne, K. R., McDonald, S. P., & Ierino, F. L. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.024 · Cited by 150
The USRDS: What You Need to Know about What It Can and Can’t Tell Us about ESRD
Foley, R. N., & Collins, A. J. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06840712 · Cited by 154
Hirakata, H., Nitta, K., Inaba, M., Shoji, T., Fujii, H., Kobayashi, S., Tabei, K., Joki, N., Hase, H., Nishimura, M., et al. (2012) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2012.01088.x · Cited by 145
PROGRESS IN UREMIC TOXIN RESEARCH: The Role of Oxidative Stress in Chronic Kidney Disease
Massy, Z. A., Stenvinkel, P., & Drüeke, T. B. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00590.x · Cited by 137
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez-Castelao, A., Górriz, J. L., Bover, J., Segura-de la Morena, J., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Atención Primaria · doi:10.1016/j.aprim.2014.09.002 · Cited by 132
Nakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1041 · Cited by 146
Mechanisms and consequences of carbamoylation
Delanghe, S. E., Delanghe, J., Speeckaert, R., Biesen, W. V., & Speeckaert, M. M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.103 · Cited by 147
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies
Drechsler, C., Delgado, G., Wanner, C., Blouin, K., Pilz, S., Tomaschitz, A., Kleber, M. E., Dressel, A., Willmes, C., Krane, V., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010093 · Cited by 149
Self-citationCKD and Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapeutic Approaches
Whitman, I. R., Feldman, H. I., & Deo, R. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010037 · Cited by 134
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784 · Cited by 114
HDL-inflammatory index correlates with poor outcome in hemodialysis patients
Kalantar‐Zadeh, K., Kopple, J. D., Kamranpour, N., Fogelman, A. M., & Navab, M. (2007) · Kidney International · doi:10.1038/sj.ki.5002491 · Cited by 139
Inflammation as a risk factor and target for therapy in chronic kidney disease
Miyamoto, T., Carrero, J. J., & Stenvinkel, P. (2011) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e32834ad504 · Cited by 128
Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1011125 · Cited by 122
de Lorgeril, M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.184 · Cited by 130
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins
Florens, N., Calzada, C., Lyasko, E., Juillard, L., & Soulage, C. O. (2016) · Toxins · doi:10.3390/toxins8120376 · Cited by 140
Rysz, J., Gluba-Brzózka, A., Rysz-Górzyńska, M., & Franczyk, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020601 · Cited by 136
Shoji, T., Masakane, I., Watanabe, Y., Iseki, K., & Tsubakihara, Y. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09961110 · Cited by 133
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 132
Ethier, J. H., Bragg‐Gresham, J. L., Piera, L., Akizawa, T., Asano, Y., Mason, N. A., Gillespie, B. W., & Young, E. W. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.007 · Cited by 124
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 128
Antioxidant therapy in hemodialysis patients: a systematic review
Coombes, J. S., & Fassett, R. G. (2011) · Kidney International · doi:10.1038/ki.2011.341 · Cited by 123
Carotid Intima-Media Thickness in Children with CKD: Results from the CKiD Study
Brady, T. M., Schneider, M. F., Flynn, J. T., Cox, C., Samuels, J., Saland, J. M., White, C. T., Furth, S. L., Warady, B. A., & Mitsnefes, M. M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03130312 · Cited by 133
Inflammation in Renal Transplantation
Abedini, S., Holme, I., Diaeresis]rz, W. M., Weihrauch, G., Diaeresis]m, B. F., Jardine, A. G., Cole, E., Maes, B., Neumayer, H., Grönhagen‐Riska, C., et al. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00930209 · Cited by 133
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 127
Statin Use and Hospitalization for Sepsis in Patients With Chronic Kidney Disease
Gupta, R., Plantinga, L. C., Fink, N. E., Melamed, M. L., Coresh, J., Fox, C. S., Levin, N. W., & Powe, N. R. (2007) · JAMA · doi:10.1001/jama.297.13.1455 · Cited by 124
The Challenge of Sudden Death in Dialysis Patients
Ritz, E., & Wanner, C. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04571007 · Cited by 129
Self-citationPredictors of Survival after Cardiac Arrest in Outpatient Hemodialysis Clinics
Pun, P. H., Lehrich, R. W., Smith, S. R., & Middleton, J. P. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02360706 · Cited by 122
Glycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients
Drechsler, C., Krane, V., Ritz, E., März, W., & Wanner, C. (2009) · Circulation · doi:10.1161/circulationaha.109.857268 · Cited by 128
Self-citationAtorvastatin for lowering lipids
Adams, S. P., Tsang, M., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub3 · Cited by 123
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Navaneethan, S. D., Bansal, N., Cavanaugh, K. L., Chang, A. R., Crowley, S. T., Delgado, C., Estrella, M. M., Ghossein, C., Ikizler, T. A., Koncicki, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.003 · Cited by 126
IL-1β Receptor Antagonist Reduces Inflammation in Hemodialysis Patients
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C., & Ikizler, T. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070760 · Cited by 117
Himmelfarb, J. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00659.x · Cited by 120
Cardiovascular disease in patients with chronic kidney disease
Hutchison, A. J. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6206 · Cited by 149
Rosuvastatin in Diabetic Hemodialysis Patients
Holdaas, H., Holme, I., Schmieder, R. E., Jardine, A. G., Zannad, F., Norby, G. E., & Fellström, B. C. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010090987 · Cited by 118
Garimella, P. S., Hart, P. D., O’Hare, A. M., DeLoach, S. S., Herzog, C. A., & Hirsch, A. T. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.340 · Cited by 123
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients
Tepel, M., Hopfenmueller, W., Scholze, A., Maier, A., & Zidek, W. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn304 · Cited by 124
KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD
Sarnak, M. J., Bloom, R. D., Muntner, P., Rahman, M., Saland, J. M., Wilson, P. W. F., & Fried, L. P. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.005 · Cited by 127
Aslam, S., Santha, T., Leone, A., & Wilcox, C. S. (2006) · Kidney International · doi:10.1038/sj.ki.5001983 · Cited by 123
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 131
New pharmacological treatments for improving renal outcomes in diabetes
Declèves, A., & Sharma, K. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.57 · Cited by 120
Clinical relevance of FGF-23 in chronic kidney disease
Seiler, S., Heine, G. H., & Fliser, D. (2009) · Kidney International · doi:10.1038/ki.2009.405 · Cited by 128
McCullough, P. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03871106 · Cited by 144
Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.025 · Cited by 115
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know
Kovesdy, C. P., & Quarles, L. D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft065 · Cited by 111
Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench
Naderi, N., Kleine, C., Park, C., Hsiung, J., Soohoo, M., Tantisattamo, E., Streja, E., Kalantar‐Zadeh, K., & Moradi, H. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.001 · Cited by 121
Valvular heart disease and calcification in CKD: more common than appreciated
Ureña, P., D’Marco, L., Raggi, P., García–Moll, X., Brandenburg, V. M., Mazzaferro, S., Lieber, A., Guirado, L., & Bover, J. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz133 · Cited by 122
Byrne, P., Demasi, M., Jones, M., Smith, S. M., O’Brien, K. K., & DuBroff, R. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0134 · Cited by 114
Vaziri, N. D. (2010) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2010.05.010 · Cited by 121
HMG CoA reductase inhibitors (statins) for dialysis patients
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Nigwekar, S. U., Hegbrant, J., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub5 · Cited by 114
Chertow, G. M., Chang, A. M., Felker, G. M., Heise, M. A., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R. A., Gibson, C. M., Goodman, S. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03043-1 · Cited by 113
Charytan, D. M., Himmelfarb, J., Ikizler, T. A., Raj, D. S., Hsu, J. Y., Landis, J. R., Anderson, A. H., Hung, A. M., Mehrotra, R., Sharma, S., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.08.034 · Cited by 112
Moradi, H., Streja, E., Kashyap, M. L., Vaziri, N. D., Fonarow, G. C., & Kalantar‐Zadeh, K. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu022 · Cited by 117
β-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis
Weir, M. A., Dixon, S. N., Fleet, J. L., Roberts, M. A., Hackam, D. G., Oliver, M. J., Suri, R. S., Quinn, R. R., Ozair, S., Beyea, M. M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040324 · Cited by 111
Edwards, N. C., Hirth, A., Ferro, C. J., Townend, J., & Steeds, R. P. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.09.013 · Cited by 110
Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It?
Carrero, J. J., Yılmaz, M. İ., Lindholm, B., & Stenvinkel, P. (2008) · Blood Purification · doi:10.1159/000126926 · Cited by 110
Residual microvascular risk in diabetes: unmet needs and future directions
Fioretto, P., Dodson, P. M., Ziegler, D., & Rosenson, R. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.213 · Cited by 115
Therapeutic strategies to slow chronic kidney disease progression
Wühl, E., & Schaefer, F. S. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0789-y · Cited by 122
Racial and survival paradoxes in chronic kidney disease
Kalantar‐Zadeh, K., Kovesdy, C. P., Derose, S. F., Horwich, T. B., & Fonarow, G. C. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0570 · Cited by 110
Predictors of Survival in Patients With End-Stage Renal Disease Evaluated for Kidney Transplantation
Hage, F. G., Smalheiser, S. A., Zoghbi, G. J., Perry, G. J., Deierhoi, M. H., Warnock, D. G., Iskandrian, A. E., de Mattos, A. M., & Aqel, R. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.045 · Cited by 108
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.